{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:14:20Z","timestamp":1734671660887,"version":"3.32.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,18]]},"DOI":"10.7759\/cureus.75982","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:05:38Z","timestamp":1734591938000},"source":"Crossref","is-referenced-by-count":0,"title":["Changes in Vascular Endothelial Growth Factor and Development of Hepatocellular Carcinoma in Direct-Acting Antiviral Drugs (DAAs)-Treated Hepatocellular Carcinoma (HCC) Patients"],"prefix":"10.7759","author":[{"given":"Amro  M","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba H","family":"Orabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Abdel-Gawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omran","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safwat  S","family":"Sawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona M","family":"Abdelmeguid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emad","family":"Abdelrazzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Ead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa A","family":"Haridy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang JD","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019, 16:589-604. 10.1038\/s41575-019-0186-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012414-040323","article-title":"Hepatitis C virus-associated cancer","volume":"10","author":"Lin MV","year":"2015","unstructured":"Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol. 2015, 10:345-70. 10.1146\/annurev-pathol-012414-040323","journal-title":"Annu Rev Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan RL","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013, 158:329-37. 10.7326\/0003-4819-158-5-201303050-00005","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia O","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017, 166:637-48. 10.7326\/M16-2575","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2019.03.001","article-title":"Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: the debate continues - a mini-review","volume":"17","author":"El Kassas M","year":"2019","unstructured":"El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: the debate continues - a mini-review. J Adv Res. 2019, 17:43-8. 10.1016\/j.jare.2019.03.001","journal-title":"J Adv Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3892\/or.7.4.725","article-title":"Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues","volume":"7","author":"Yamaguchi R","year":"2000","unstructured":"Yamaguchi R, Yano H, Nakashima Y, et al.. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 2000, 7:725-9. 10.3892\/or.7.4.725","journal-title":"Oncol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-011-1304-2","article-title":"VEGF is essential for the growth and migration of human hepatocellular carcinoma cells","volume":"39","author":"Zhang L","year":"2012","unstructured":"Zhang L, Wang JN, Tang JM, et al.. VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep. 2012, 39:5085-93. 10.1007\/s11033-011-1304-2","journal-title":"Mol Biol Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2686-2","article-title":"CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF","volume":"36","author":"Li Y","year":"2015","unstructured":"Li Y, Zhai Z, Liu D, et al.. CD105 promotes hepatocarcinoma cell invasion and metastasis through VEGF. Tumour Biol. 2015, 36:737-45. 10.1007\/s13277-014-2686-2","journal-title":"Tumour Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i6.600","article-title":"Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients","volume":"13","author":"Alzamzamy A","year":"2021","unstructured":"Alzamzamy A, Elsayed H, Abd Elraouf M, Eltoukhy H, Megahed T, Aboubakr A. Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients. World J Gastrointest Oncol. 2021, 13:600-11. 10.4251\/wjgo.v13.i6.600","journal-title":"World J Gastrointest Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12668","article-title":"National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care","volume":"24","author":"El-Akel W","year":"2017","unstructured":"El-Akel W, El-Sayed MH, El Kassas M, et al.. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017, 24:262-7. 10.1111\/jvh.12668","journal-title":"J Viral Hepat"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling RK","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006, 43:1317-25. 10.1002\/hep.21178","journal-title":"Hepatology"},{"key":"ref12","article-title":"Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): usefulness in patients with chronic liver disease. APRI in chronic liver disease","volume":"11","author":"Yilmaz Y","year":"2011","unstructured":"Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): usefulness in patients with chronic liver disease. APRI in chronic liver disease. Hepat Mon. 2011, 11:103-6.","journal-title":"Hepat Mon"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.12.021","article-title":"Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis","volume":"152","author":"Ravi S","year":"2017","unstructured":"Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, Singal AK. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology. 2017, 152:911-2. 10.1053\/j.gastro.2016.12.021","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_82_17","article-title":"Epidemiology of liver cancer in Nile delta over a decade: a single-center study","volume":"7","author":"Abd-Elsalam S","year":"2018","unstructured":"Abd-Elsalam S, Elwan N, Soliman H, et al.. Epidemiology of liver cancer in Nile delta over a decade: a single-center study. South Asian J Cancer. 2018, 7:24-6. 10.4103\/sajc.sajc_82_17","journal-title":"South Asian J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat F","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al.. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019, 393:1453-64. 10.1016\/S0140-6736(18)32111-1","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti F","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, et al.. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016, 65:727-33. 10.1016\/j.jhep.2016.06.015","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Pi\u00f1ero F","year":"2019","unstructured":"Pi\u00f1ero F, Mendizabal M, Ridruejo E, et al.. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int. 2019, 39:1033-43. 10.1111\/liv.14041","journal-title":"Liver Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8578051","article-title":"Restoring inflammatory mediator balance after sofosbuvir-induced viral clearance in patients with chronic Hepatitis C","volume":"2018","author":"Saraiva GN","year":"2018","unstructured":"Saraiva GN, do Ros\u00e1rio NF, Medeiros T, et al.. Restoring inflammatory mediator balance after sofosbuvir-induced viral clearance in patients with chronic Hepatitis C. Mediators Inflamm. 2018, 2018:8578051. 10.1155\/2018\/8578051","journal-title":"Mediators Inflamm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcab100.039","article-title":"Vascular endothelial growth factor A in HCV infected patients before and after treatment with DAAS and its possible relation to HCC development","volume":"114","author":"Helal EM","year":"2021","unstructured":"Helal EM, Ibraheem WA, Sayed MM, Salama MM, EL Ghandour AM, Salama AB. Vascular endothelial growth factor A in HCV infected patients before and after treatment with DAAS and its possible relation to HCC development. QJM. 2021, 114:hcab100.039. 10.1093\/qjmed\/hcab100.039","journal-title":"QJM"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-020-00073-5","article-title":"Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals","volume":"11","author":"ElGhandour AM","year":"2021","unstructured":"ElGhandour AM, Bayoumy EM, Ibrahim WA, Sayed MM, Salama AB, Teama NM, Salama  MM. Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals. Egypt Liver J. 2021, 11:5. 10.1186\/s43066-020-00073-5","journal-title":"Egypt Liver J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167934","article-title":"DAAS rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment","volume":"11","author":"Villani R","year":"2016","unstructured":"Villani R, Facciorusso A, Bellanti F, et al.. DAAS rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment. PLoS One. 2016, 11:e0167934. 10.1371\/journal.pone.0167934","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw457","article-title":"Direct-acting antiviral-induced hepatitis c virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C","volume":"214","author":"Hengst J","year":"2016","unstructured":"Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M, Wedemeyer H. Direct-acting antiviral-induced hepatitis c virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis. 2016, 214:1965-74. 10.1093\/infdis\/jiw457","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-017-0789-1","article-title":"Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C","volume":"11","author":"Kawaguchi T","year":"2018","unstructured":"Kawaguchi T, Ide T, Koga H, et al.. Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C. Clin J Gastroenterol. 2018, 11:69-74. 10.1007\/s12328-017-0789-1","journal-title":"Clin J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-021-00108-5","article-title":"Effect of directly acting anti-viral agents on immunological imprints in chronic HCV-4a patients: interleukin-10 and vascular endothelial growth factor genes expression level","volume":"11","author":"Naga IS","year":"2021","unstructured":"Naga IS, Kamel AA, Ooda SA, Fath Elbab HM, El-Sharkawy RM. Effect of directly acting anti-viral agents on immunological imprints in chronic HCV-4a patients: interleukin-10 and vascular endothelial growth factor genes expression level. Egypt Liver J. 2021, 11:35. 10.1186\/s43066-021-00108-5","journal-title":"Egypt Liver J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00057","article-title":"Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct acting agents","volume":"5","author":"Nguyen K","year":"2017","unstructured":"Nguyen K, Jimenez M, Moghadam N, et al.. Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct acting agents. J Clin Transl Hepatol. 2017, 5:43-9. 10.14218\/JCTH.2016.00057","journal-title":"J Clin Transl Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001400","article-title":"Clinical impact of serum \u03b1-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals","volume":"31","author":"Fouad R","year":"2019","unstructured":"Fouad R, Elsharkawy A, Abdel Alem S, et al.. Clinical impact of serum \u03b1-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol. 2019, 31:1129-34. 10.1097\/MEG.0000000000001400","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry R","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, et al.. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017, 67:1204-12. 10.1016\/j.jhep.2017.07.025","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13758","article-title":"Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon","volume":"32","author":"Elsharkawy A","year":"2017","unstructured":"Elsharkawy A, Alem SA, Fouad R, et al.. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol. 2017, 32:1624-30. 10.1111\/jgh.13758","journal-title":"J Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner JA","year":"2017","unstructured":"Bachofner JA, Valli PV, Kr\u00f6ger A, et al.. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017, 37:369-76. 10.1111\/liv.13256","journal-title":"Liver Int"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25210","article-title":"Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort","volume":"90","author":"Alem SA","year":"2018","unstructured":"Alem SA, Said M, Anwar I, et al.. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort. J Med Virol. 2018, 90:1508-15. 10.1002\/jmv.25210","journal-title":"J Med Virol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/259283-changes-in-vascular-endothelial-growth-factor-and-development-of-hepatocellular-carcinoma-in-direct-acting-antiviral-drugs-daas-treated-hepatocellular-carcinoma-hcc-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:05:40Z","timestamp":1734591940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/259283-changes-in-vascular-endothelial-growth-factor-and-development-of-hepatocellular-carcinoma-in-direct-acting-antiviral-drugs-daas-treated-hepatocellular-carcinoma-hcc-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.75982","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}